Patent application number | Description | Published |
20110256018 | Ni-Based Single Crystal Superalloy with Good Creep Property - A Ni-based single crystal superalloy with good resistance to creep deformation and creep life at a high temperature is formed by adjusting the quantity of relatively inexpensive alloy elements while minimizing the quantity of expensive alloy elements. The Ni-based single crystal superalloy with good creep properties comprises Co: 11.5˜13.5%, Cr: 3.0˜5.0%, Mo: 0.7˜2.0%, W: 8.5˜10.5%, Al: 4.5˜6.5%, Ti: 0.5˜2.0%, Ta: 6.0˜8.0%, Re: 2.0˜4.0%, Ru: 0.1˜2.0% in Weight %, with the rest of the superalloy comprising Ni and other inevitable impurities. In addition, the superalloy has a mixed structure of the γ matrix and γ′ particles. | 10-20-2011 |
20120237391 | Ni-Base Single Crystal Superalloy with Enhanced Creep Property - The present invention provides Ni-base single crystal superalloy with good high-temperature property, particularly long creep life and excellent resistance to creep deformation, by adjusting content of Al and Ti that form a gamma prime (γ′), a major hardening phase of the Ni-base single crystal superalloy. The Ni-base single crystal superalloy comprise Co: 11.5˜13.5%, Cr: 3.0˜5.0%, Mo: 0.7˜2.0%, W: 8.5˜10.5%, Al: 3.5˜5.5%, Ti: 2.5˜4.5%, Ta: 6.0˜8.0%, Re: 2.0˜4.0%, Ru: 0.1˜2.0% in Weight %, and the rest is Ni and other inevitable impurities. And composition ratio of Al/Ti is 0.7˜2.2. In addition, the superalloy has a mixed structure of the γ matrix and γ′ particles. | 09-20-2012 |
Patent application number | Description | Published |
20140087939 | Metal-Carbon Composite Supported Catalyst for Hydrogen Production Using Co-Evaporation and Method of Preparing the Same - A metal-carbon composite supported catalyst for hydrogen production using co-evaporation and a method of preparing the same, wherein the catalyst is configured such that a metal-carbon composite having a core-shell structure resulting from co-evaporation is supported on the surface of an oxide-based support coated with carbon, thereby maintaining superior durability without agglomeration even in a catalytic reaction at a high temperature. Because part or all of the surface of metal is covered with the carbon shell, even when the catalyst is applied under severe reaction conditions including high temperatures, long periods of time, acidic or alkaline states, etc., the metal particles do not agglomerate or are not detached, and do not corrode, thus exhibiting high performance and high durability. Therefore, inactivation of the catalyst or the generation of side reactions can be prevented, so that the catalyst can be efficiently utilized in hydrogen production. | 03-27-2014 |
20140245670 | ISOLATING DEVICE, METHOD OF REPLACING ISOLATING STRUCTURE PART AND METHOD OF CONTROLLING LOAD OF ISOLATING STRUCTURE - Provided are an isolating device, a method of replacing an isolating structure part, and a method of controlling a load of the isolating structure part. The isolating device disposed between an upper structure and a lower structure includes an isolating structure part for performing an isolating function, and a height-adjustable part disposed on at least one of positions between the isolating structure part and the upper structure and between the isolating structure part and the lower structure, the height-adjustable part being adjusted in height by supplying or discharging fluid therein or therefrom. | 09-04-2014 |
Patent application number | Description | Published |
20150118255 | LIQUID FORMULATION OF HIGHLY CONCENTRATED LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE - The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same. | 04-30-2015 |
20150190528 | LIQUID FORMULATION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE - The present invention relates to a liquid formulation of a combination of long-acting insulin and insulinotropic peptide, comprising insulin which is a physiologically active peptide, insulinotropic peptide, and albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent; and a method for preparing the liquid formulation. The liquid formulation of the present invention does not contain a human serum albumin and potentially toxic factors to the body, and thus it has excellent storage stability for insulin conjugate and insulinotropic peptide conjugate at high concentration, without a risk of viral contamination. | 07-09-2015 |
20150196643 | LIQUID FORMULATION OF LONG-ACTING INSULIN CONJUGATE - The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection. | 07-16-2015 |
20150238629 | LIQUID FORMULATION OF LONG ACTING INSULINOTROPIC PEPTIDE CONJUGATE - The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration. | 08-27-2015 |